Access cutting-edge liver cancer treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access liver cancer specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related liver cancer treatment provided free
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Dose esc
Sponsor: Teclison Ltd.
Check if you qualify for this liver cancer clinical trial in Palo Alto, CA
If you're searching for liver cancer treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced liver cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.